Literature DB >> 15216508

Quantification of cyclophosphamide and its metabolites in urine using liquid chromatography/tandem mass spectrometry.

Dirk Kasel1, Alexander Jetter, Steffi Harlfinger, Wilhelm Gebhardt, Uwe Fuhr.   

Abstract

A reliable and easy to use liquid chromatography/tandem mass spectrometry (LC/MS/MS) method was developed for the simultaneous quantification of urinary concentrations of cyclophosphamide (CP) and its main metabolites excreted in urine, i.e. N-dechloroethylcyclophosphamide (DCL-CP), 4-ketocyclophosphamide (4KetoCP), and carboxyphosphamide (CarboxyCP). Sample preparation consisted of dilution of urine with an aqueous solution of the internal standard D(4)-CP and methanol, and centrifugation. LC/MS/MS detection was performed using a triple-quadrupole mass spectrometer working in selected reaction monitoring mode. All analytes were quantified in a single run within 11.5 min. The limits of detection were 5 ng/mL for CP and 4KetoCP, 1 ng/mL for DCL-CP, and 30 ng/mL for CarboxyCP. Quantification ranges were adjusted to the expected concentrations in 24-h urine collections of patients treated with a polychemotherapy regimen (3-175 microg/mL for CP, 0.5-27 microg/mL for 4KetoCP and 0.17-9 microg/mL for CarboxyCP and DCL-CP, respectively). The method was validated according to international guidelines of the ICH and the FDA. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15216508     DOI: 10.1002/rcm.1508

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  6 in total

1.  Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity.

Authors:  Stefan Wilde; Alexander Jetter; Stephan Rietbrock; Dirk Kasel; Andreas Engert; Andreas Josting; Beate Klimm; Georg Hempel; Stefanie Reif; Ulrich Jaehde; Ute Merkel; Dagmar Busse; Matthias Schwab; Volker Diehl; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Occurrence of cyclophosphamide and epirubicin in wastewaters by direct injection analysis-liquid chromatography-high-resolution mass spectrometry.

Authors:  Cristian Gómez-Canela; Nuria Cortés-Francisco; Xavier Oliva; Cristina Pujol; Francesc Ventura; Silvia Lacorte; Josep Caixach
Journal:  Environ Sci Pollut Res Int       Date:  2012-03-01       Impact factor: 4.223

Review 3.  A review of high performance liquid chromatographic-mass spectrometric urinary methods for anticancer drug exposure of health care workers.

Authors:  Patricia I Mathias; Thomas H Connor; Clayton B'Hymer
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2017-06-19       Impact factor: 3.205

Review 4.  Revisited Cyclophosphamide in the Treatment of Lupus Nephritis.

Authors:  Xiao-Ying Quan; Hao-Tao Chen; Si-Qin Liang; Chen Yang; Cui-Wei Yao; Yong-Zhi Xu; Hua-Feng Liu; Ning An
Journal:  Biomed Res Int       Date:  2022-05-26       Impact factor: 3.246

5.  Validation of urinary excretion of cyclophosphamide as a biomarker of exposure by studying its renal clearance at high and low plasma concentrations in cancer patients.

Authors:  Maria Hedmer; Peter Höglund; Eva Cavallin-Ståhl; Maria Albin; Bo A G Jönsson
Journal:  Int Arch Occup Environ Health       Date:  2007-06-20       Impact factor: 3.015

6.  Oxazaphosphorine bioactivation and detoxification The role of xenobiotic receptors.

Authors:  Duan Wang; Hongbing Wang
Journal:  Acta Pharm Sin B       Date:  2012-04-01       Impact factor: 11.413

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.